The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
Abstract
BACKGROUND: Fabry disease is an X-linked disorder of glycosphingolipid catabolism that is the result of an intracellular deficiency in the lysosomal enzyme alpha-galactosidase A (alpha-Gal A). This enzymatic defect results in the accumulation of globotriaosylceramide (Gb(3)) within cells and causes progressive neurological, cardiovascular and renal dysfunction. Our objective is to describe the safety and renal effects of long-term enzyme replacement therapy. METHODS: This was a single centre, prospective open-label treatment trial in 25 adult male Fabry patients who had completed a 6-month randomized placebo-controlled study and subsequently enrolled in an open-label extension study. Patients were treated every other week with agalsidase alfa (0.2 mg/kg) infused intravenously over 40 min. The main outcome measures were safety, antibody response and renal glomerular filtration rate (GFR). RESULTS: During the 4-4.5 years of enzyme replacement therapy, all eligible subjects were able to transition to home therapy. Eight patients developed persistent IgG antibodies to agalsidase alfa, but IgE antibodies were not detected in any patient. The development of IgG antibodies appeared not to affect any clinical end points. Estimated GFR remained stable in subgroups of patients with Stage I (GFR >90 ml/min) or Stage II (GFR 60-89 ml/min) chronic kidney disease at baseline. In contrast, in the subgroup of patients with Stage III chronic kidney disease (GFR 30-59 ml/min), the slope of the decline in GFR was reduced compared with comparable historical controls, suggesting that enzyme replacement therapy was slowing the decline of renal function in this susceptible population. CONCLUSIONS: Long-term enzyme replacement therapy with agalsidase alfa is safe and may slow the progressive decline in renal function that was commonly observed in adult males with Fabry disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Self-citationDoqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
Enzymatic Defect in Fabry's Disease: Ceramidetrihexosidase Deficiency
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L., & Laster, L. (1967) · New England Journal of Medicine · doi:10.1056/nejm196705252762101 · Cited by 1,053
Self-citationReport on Management of Renal Failure in Europe, XXIV, 1993
Valderrabano, F., Jones, E. H. P., & Mallick, N. P. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.supp5.1 · Cited by 699
MacDermot, K. D., Holmes, A., & Miners, A. H. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.769 · Cited by 681
BRANTON, M. H., SCHIFFMANN, R., SABNIS, S. G., MURRAY, G. J., QUIRK, J. M., ALTARESCU, G., GOLDFARB, L., BRADY, R. O., BALOW, J. E., AUSTIN, H. A., et al. (2002) · Medicine · doi:10.1097/00005792-200203000-00003 · Cited by 461
Self-citationWhybra, C., Kampmann, C., Krummenauer, F., Ries, M., Mengel, E., Miebach, E., Baehner, F., Kim, K., Bajbouj, M., Schwarting, A., et al. (2004) · Clinical Genetics · doi:10.1111/j.1399-0004.2004.00219.x · Cited by 266
Self-citationMoore, D. F., Scott, L. T. C., Gladwin, M. T., Altarescu, G., Kaneski, C., Suzuki, K., Pease-Fye, M., Ferri, R., Brady, R. O., Herscovitch, P., et al. (2001) · Circulation · doi:10.1161/hc3801.096352 · Cited by 252
Self-citation
Cited by
Germain, D. P. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-30 · Cited by 1,198
Fabry disease revisited: Management and treatment recommendations for adult patients
Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.02.014 · Cited by 650
Muenzer, J., Wraith, J. E., Beck, M., Giugliani, R., Harmatz, P., Eng, C. M., Vellodi, A., Martin, R., Ramaswami, U., Gucsavas-Calikoglu, M., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000232477.37660.fb · Cited by 584
Schiffmann, R., Warnock, D. G., Banikazemi, M., Bultas, J., Linthorst, G. E., Packman, S., Sorensen, S. A., Wilcox, W. R., & Desnick, R. J. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp031 · Cited by 368
Self-citationVedder, A. C., Cox-Brinkman, J., Hollak, C. E. M., Linthorst, G. E., Groener, J. E. M., Helmond, M. T. J., Scheij, S., & Aerts, J. M. F. G. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.04.013 · Cited by 53
Metadata
- Authors
- Schiffmann, R., Ries, M., Timmons, M., Flaherty, J. T., & Brady, R. O.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-04
- Volume
- 21
- Issue
- 2
- Pages
- 345-354
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2160213856
- Cited by
- 269
- References
- 17
- FWCI
- 12.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. https://app.cochat.ai/papers/10.1093/ndt/gfi152
- The paper
- Schiffmann, R., Ries, M., Timmons, M., Flaherty, J. T., & Brady, R. O. (2006). Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfi152
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.